Investing.comCodex · 实盘不做把握 7/10不做原因:无增量信息
北京时间·🕒 发布 22:12:34·⟳ 抓取 22:13:03 +29s·⚡ 决策 08-28 22:31:19 +18m16s·59.9 天前
Agenus公布的BOT+BAL结直肠癌生存数据主要是7月ESMO GI已披露数据的论文发布转述
当前报道没有带来相对7月公司一手披露的新增关键事实；对AGEN.US的短线预期差不足，且该资产仍处临床/注册前阶段，不能仅因论文发表追多。
📄 原文Investing.com↗ 原文
Agenus reports survival data for colorectal cancer treatment
U.S. stocks mostly flat at the open as traders await Warsh’s Jackson Hole speech LEXINGTON, Mass. - Agenus Inc. (NASDAQ…
不做 Agenus Inc.（AGEN.US）
不做Agenus Inc.（AGEN.US）：临床数据方向正面但核心数字7月已公开，本次为论文发表/媒体转述，无新增审批、顶线、合作或收入增量，短线edge不足。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事件内容是Agenus BOT+BAL在MSS转移性结直肠癌无活动性肝转移队列的成熟Phase 1b生存数据，医学方向正面；但核心疗效、安全性和Phase 3继续推进逻辑已在2026-07-06公司新闻稿与后续行业媒体中披露，本次Investing.com报道更像论文发表后的再传播，不构成新的订单、审批、顶线读出或指引变化，因此不做。
消息传播链
- 公司一手披露同一123例Phase 1b队列的21.2个月中位OS、33%三年OS、21% ORR和安全性结果。
- 肿瘤行业媒体同日复述ESMO GI数据，说明核心疗效数字已公开传播。
- Investing.com报道Clinical Cancer Research发表后的同一BOT+BAL Phase 1b数据，未见新增监管或商业化里程碑。
关键理由
- BOT+BAL在难治MSS mCRC队列中显示21.2个月中位OS、33%三年OS和21% ORR，临床信号方向为正。
- 公司8月二季度更新已披露ROBBIN Phase 3计划与二季度640万美元预商业产品收入，当前报道没有改变收入基数或可触达市场测算。
主要风险
- 本次只是Phase 1b论文/媒体转述，尚未形成随机注册数据或监管批准，新增业绩量级无法量化。
- 同一核心数据已于2026-07-06公开，短线price-in风险高。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-07-06 · 影响 weakens
同一疗效数据已由公司7月6日披露并被行业媒体传播，削弱8月28日转述的短线预期差。
检索:Agenus BOT+BAL colorectal cancer July 2026 same data already reported 原文 ↗ - 做多前查反向 · 来源 web · 日期 2026-08-06 · 影响 weakens
公司近期更新显示仍处Phase 3推进前后阶段，当前论文发表未改变注册风险或商业化时间线。
检索:Agenus ROBBIN BATTMAN phase 3 BOT BAL colorectal cancer financing August 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足不影响结论；决定性因素是同一疗效数据已在7月公开。
方向:临床疗效论文发表通常方向偏正面，但本次核心数据已提前以公司一手新闻稿和会议摘要传播。
涨幅量级:未使用先例校准幅度，因为当前结论由无新增事实主导，不进入交易。
形态:无需用先例判断追涨空间；主要风险是旧数据再传播导致见光后无增量。
工具执行结果 · 成功 2 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,086 字
U.S. stocks mostly flat at the open as traders await Warsh’s Jackson Hole speech
LEXINGTON, Mass. - Agenus Inc. (NASDAQ:AGEN) announced the publication of Phase 1b trial results for its botensilimab and balstilimab combination therapy in heavily pretreated patients with microsatellite-stable metastatic colorectal cancer without active liver metastases, according to a press release statement.
The study, published in Clinical Cancer Research, evaluated 123 patients who received a median of three prior lines of therapy. The treatment combination demonstrated a median overall survival of 21.2 months and a three-year overall survival rate of 33%. Patients received a median of two botensilimab doses and six balstilimab doses.
The confirmed objective response rate was 21%, including three complete responses and 23 partial responses. Median duration of response was not reached, with responses extending to at least 37.4 months. Disease control rate was 69% at six weeks.
In a subgroup of 37 patients who had received a median of five prior lines of therapy, the treatment showed a 22% confirmed objective response rate, median overall survival of 16.2 months, and a three-year overall survival rate of 30%.
Exploratory biomarker analyses showed responses occurred in patients with low tumor mutational burden and no detectable PD-L1 expression. Neither biomarker was associated with response in the evaluable population.
The most common immune-mediated adverse event was diarrhea or colitis, which resolved in 98% of affected patients with a median time to resolution of 14 days. No treatment-related deaths occurred.
Efficacy was consistent across the two botensilimab dose levels evaluated, with a 21% objective response rate at both 1 mg/kg and 2 mg/kg. Lower rates of immune-mediated adverse events were observed with the 1 mg/kg dose.
The C-800-01 trial is a Phase 1b study evaluating botensilimab with or without balstilimab in patients with advanced solid tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
LEXINGTON, Mass. - Agenus Inc. (NASDAQ:AGEN) announced the publication of Phase 1b trial results for its botensilimab and balstilimab combination therapy in heavily pretreated patients with microsatellite-stable metastatic colorectal cancer without active liver metastases, according to a press release statement.
The study, published in Clinical Cancer Research, evaluated 123 patients who received a median of three prior lines of therapy. The treatment combination demonstrated a median overall survival of 21.2 months and a three-year overall survival rate of 33%. Patients received a median of two botensilimab doses and six balstilimab doses.
The confirmed objective response rate was 21%, including three complete responses and 23 partial responses. Median duration of response was not reached, with responses extending to at least 37.4 months. Disease control rate was 69% at six weeks.
In a subgroup of 37 patients who had received a median of five prior lines of therapy, the treatment showed a 22% confirmed objective response rate, median overall survival of 16.2 months, and a three-year overall survival rate of 30%.
Exploratory biomarker analyses showed responses occurred in patients with low tumor mutational burden and no detectable PD-L1 expression. Neither biomarker was associated with response in the evaluable population.
The most common immune-mediated adverse event was diarrhea or colitis, which resolved in 98% of affected patients with a median time to resolution of 14 days. No treatment-related deaths occurred.
Efficacy was consistent across the two botensilimab dose levels evaluated, with a 21% objective response rate at both 1 mg/kg and 2 mg/kg. Lower rates of immune-mediated adverse events were observed with the 1 mg/kg dose.
The C-800-01 trial is a Phase 1b study evaluating botensilimab with or without balstilimab in patients with advanced solid tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。